vs
Side-by-side financial comparison of PUMA BIOTECHNOLOGY, INC. (PBYI) and VICOR CORP (VICR). Click either name above to swap in a different company.
VICOR CORP is the larger business by last-quarter revenue ($113.0M vs $75.5M, roughly 1.5× PUMA BIOTECHNOLOGY, INC.). On growth, PUMA BIOTECHNOLOGY, INC. posted the faster year-over-year revenue change (27.7% vs 20.2%). Over the past eight quarters, PUMA BIOTECHNOLOGY, INC.'s revenue compounded faster (31.3% CAGR vs 14.7%).
Puma Biotechnology is a publicly traded biopharmaceutical company headquartered in Los Angeles, CA.
Vicor Corporation is a manufacturer of power modules headquartered in Andover, Massachusetts.
PBYI vs VICR — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $75.5M | $113.0M |
| Net Profit | — | $20.7M |
| Gross Margin | 69.3% | — |
| Operating Margin | 22.7% | 59.7% |
| Net Margin | — | 18.3% |
| Revenue YoY | 27.7% | 20.2% |
| Net Profit YoY | — | 713.9% |
| EPS (diluted) | $0.26 | $0.44 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $113.0M | ||
| Q4 25 | $75.5M | $107.3M | ||
| Q3 25 | $54.5M | $110.4M | ||
| Q2 25 | $52.4M | $96.0M | ||
| Q1 25 | $46.0M | $94.0M | ||
| Q4 24 | $59.1M | $96.2M | ||
| Q3 24 | $80.5M | $93.2M | ||
| Q2 24 | $47.1M | $85.9M |
| Q1 26 | — | $20.7M | ||
| Q4 25 | — | $46.5M | ||
| Q3 25 | $8.8M | $28.3M | ||
| Q2 25 | $5.9M | $41.2M | ||
| Q1 25 | $3.0M | $2.5M | ||
| Q4 24 | — | $10.2M | ||
| Q3 24 | $20.3M | $11.6M | ||
| Q2 24 | $-4.5M | $-1.2M |
| Q1 26 | — | — | ||
| Q4 25 | 69.3% | 55.4% | ||
| Q3 25 | 77.7% | 57.5% | ||
| Q2 25 | 76.5% | 95.9% | ||
| Q1 25 | 77.1% | 47.2% | ||
| Q4 24 | 76.4% | 52.4% | ||
| Q3 24 | 63.9% | 49.1% | ||
| Q2 24 | 77.4% | 49.8% |
| Q1 26 | — | 59.7% | ||
| Q4 25 | 22.7% | 14.6% | ||
| Q3 25 | 17.6% | 18.9% | ||
| Q2 25 | 12.7% | 47.3% | ||
| Q1 25 | 8.7% | -0.2% | ||
| Q4 24 | 22.6% | 9.6% | ||
| Q3 24 | 27.4% | 5.8% | ||
| Q2 24 | -4.6% | 0.2% |
| Q1 26 | — | 18.3% | ||
| Q4 25 | — | 43.4% | ||
| Q3 25 | 16.2% | 25.6% | ||
| Q2 25 | 11.2% | 42.9% | ||
| Q1 25 | 6.5% | 2.7% | ||
| Q4 24 | — | 10.7% | ||
| Q3 24 | 25.2% | 12.4% | ||
| Q2 24 | -9.6% | -1.4% |
| Q1 26 | — | $0.44 | ||
| Q4 25 | $0.26 | $1.01 | ||
| Q3 25 | $0.17 | $0.63 | ||
| Q2 25 | $0.12 | $0.91 | ||
| Q1 25 | $0.06 | $0.06 | ||
| Q4 24 | $0.40 | $0.24 | ||
| Q3 24 | $0.41 | $0.26 | ||
| Q2 24 | $-0.09 | $-0.03 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $97.5M | $404.2M |
| Total DebtLower is stronger | $22.7M | — |
| Stockholders' EquityBook value | $130.3M | $754.1M |
| Total Assets | $216.3M | $804.9M |
| Debt / EquityLower = less leverage | 0.17× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $404.2M | ||
| Q4 25 | $97.5M | $402.8M | ||
| Q3 25 | $94.4M | $362.4M | ||
| Q2 25 | $96.0M | $338.5M | ||
| Q1 25 | $93.2M | $296.1M | ||
| Q4 24 | $101.0M | $277.3M | ||
| Q3 24 | $96.7M | $267.6M | ||
| Q2 24 | $96.8M | $251.9M |
| Q1 26 | — | — | ||
| Q4 25 | $22.7M | — | ||
| Q3 25 | $34.0M | — | ||
| Q2 25 | $45.3M | — | ||
| Q1 25 | $56.7M | — | ||
| Q4 24 | $68.0M | — | ||
| Q3 24 | $79.3M | — | ||
| Q2 24 | $90.7M | — |
| Q1 26 | — | $754.1M | ||
| Q4 25 | $130.3M | $711.6M | ||
| Q3 25 | $115.3M | $630.1M | ||
| Q2 25 | $104.7M | $608.6M | ||
| Q1 25 | $97.1M | $580.3M | ||
| Q4 24 | $92.1M | $570.1M | ||
| Q3 24 | $71.1M | $554.6M | ||
| Q2 24 | $48.5M | $537.2M |
| Q1 26 | — | $804.9M | ||
| Q4 25 | $216.3M | $785.8M | ||
| Q3 25 | $202.9M | $710.2M | ||
| Q2 25 | $194.9M | $693.5M | ||
| Q1 25 | $196.2M | $665.0M | ||
| Q4 24 | $213.3M | $641.1M | ||
| Q3 24 | $220.7M | $632.8M | ||
| Q2 24 | $205.0M | $613.2M |
| Q1 26 | — | — | ||
| Q4 25 | 0.17× | — | ||
| Q3 25 | 0.30× | — | ||
| Q2 25 | 0.43× | — | ||
| Q1 25 | 0.58× | — | ||
| Q4 24 | 0.74× | — | ||
| Q3 24 | 1.12× | — | ||
| Q2 24 | 1.87× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $14.4M | — |
| Free Cash FlowOCF − Capex | $14.4M | — |
| FCF MarginFCF / Revenue | 19.1% | — |
| Capex IntensityCapex / Revenue | 0.0% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $41.7M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $14.4M | $15.7M | ||
| Q3 25 | $9.7M | $38.5M | ||
| Q2 25 | $14.1M | $65.2M | ||
| Q1 25 | $3.6M | $20.1M | ||
| Q4 24 | $15.6M | $10.1M | ||
| Q3 24 | $11.0M | $22.6M | ||
| Q2 24 | $1.0M | $15.6M |
| Q1 26 | — | — | ||
| Q4 25 | $14.4M | $10.2M | ||
| Q3 25 | $9.7M | $34.5M | ||
| Q2 25 | $14.1M | $59.0M | ||
| Q1 25 | $3.6M | $15.6M | ||
| Q4 24 | $15.6M | $8.4M | ||
| Q3 24 | $11.0M | $14.1M | ||
| Q2 24 | $1.0M | $9.4M |
| Q1 26 | — | — | ||
| Q4 25 | 19.1% | 9.5% | ||
| Q3 25 | 17.7% | 31.2% | ||
| Q2 25 | 26.8% | 61.5% | ||
| Q1 25 | 7.7% | 16.6% | ||
| Q4 24 | 26.4% | 8.7% | ||
| Q3 24 | 13.7% | 15.2% | ||
| Q2 24 | 2.1% | 11.0% |
| Q1 26 | — | — | ||
| Q4 25 | 0.0% | 5.2% | ||
| Q3 25 | 0.0% | 3.6% | ||
| Q2 25 | 0.0% | 6.5% | ||
| Q1 25 | 0.1% | 4.8% | ||
| Q4 24 | 0.0% | 1.8% | ||
| Q3 24 | 0.0% | 9.1% | ||
| Q2 24 | 0.0% | 7.2% |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.34× | ||
| Q3 25 | 1.10× | 1.36× | ||
| Q2 25 | 2.41× | 1.58× | ||
| Q1 25 | 1.21× | 7.93× | ||
| Q4 24 | — | 0.99× | ||
| Q3 24 | 0.54× | 1.95× | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PBYI
Segment breakdown not available.
VICR
| Product revenue | $98.0M | 87% |
| Royalty revenue | $15.0M | 13% |
